The guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug.
Inspection Record
G Production Inc. — Health Canada Inspection Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
The change control system was inadequate for ensuring changes are properly documented, evaluated, and/or approved.
Yields and/or the reconciled quantities were not checked at appropriate stages. The segregation, rotation of stock, and/or the transportation of raw materials, packaging materials, intermediates, bulk drugs, and/or finished products was inadequate.
The investigation, handling, and/or reporting of test results that were out-of-specification was inadequate.
Evaluation of production processes, equipment, and/or materials was inadequate.
The establishment and/or the maintenance of a data governance plan was inadequate. The controls were inadequate for creating, modifying, reviewing, storing, and/or retrieving records. The traceability, legibility, documentation, formatting, and/or the accuracy of records was inadequate.
The calibration, inspection, and/or qualification of the equipment, including computerized systems, was inadequate. The equipment was not set-up, designed, operated, stored, and/or maintained to prevent potential contamination of drugs by other drugs and/or by foreign material.
The importer did not ensure that the foreign sites use to fabricate, package/label, or test drug products met the requirements described in Guidance on Evidence to Demonstrate Drug GMP Compliance of Foreign Sites (GUI-0080).
The assessment, documentation, and/or procedures for considering the resale of returned drugs were inadequate.
The implementation and/or the effectiveness of the sanitation program in preventing unsanitary conditions was inadequate.
The investigation, handling, and/or reporting of test results that were out-of-specification was inadequate. The system for reviewing, revising, and approving standard operating procedures was inadequate.
The annual product quality review procedure was inadequate.
The quality control department did not ensure a thorough investigation and/or evaluation of complaints concerning potentially defective products.
About this record
Extracted automatically from the document of the Health Canada inspection on 2022-05-09. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
